Don Peterson
About Don Peterson
Don Peterson is a Senior Manager in Statistical Programming at Bristol-Myers Squibb, with over 20 years of experience in clinical trials statistical programming.
Company
Don Peterson currently works at Bristol-Myers Squibb as a Senior Manager of Statistical Programming. Located in New Jersey, United States, he contributes to the clinical development process and regulatory submissions. He plays a critical role in the technical and programming aspects of oncology and cardiovascular projects.
Title
Holding the position of Senior Manager, Statistical Programming, Don Peterson oversees the application and support of computer science and information technology methods at Bristol-Myers Squibb. His responsibilities include the programming of regulatory submissions, database development, and generating output such as tables, listings, and figures.
Education and Expertise
Don Peterson attended the Rochester Institute of Technology, where he earned a Bachelor of Science (B.S.) in Information Systems and an Associate of Arts and Sciences (A.A.S.) in Architectural and Building Sciences/Technology. His expertise spans over 20 years in clinical trials statistical programming, encompassing the design, development, and implementation of technical solutions for analyzing and reporting clinical data.
Background
Don Peterson has a rich professional history, beginning as a Programmer/Analyst at Greenwich Pharmaceuticals Inc. from 1992 to 1994. He continued as a Statistical Programmer at PSCI from 1995 to 2003 and then as Principal Statistical Programmer at AstraZeneca from 2003 to 2015. Since joining Bristol-Myers Squibb, Don has focused on overseeing regulatory submission programming, technical consulting, and driving the development of innovative clinical trial programming strategies.
Achievements
Throughout his career, Don Peterson has developed collaborative relationships and worked effectively within departments, with external vendors, and as part of cross-functional teams. His contributions include providing comprehensive programming expertise, ensuring alignment of priorities, and communicating effectively regarding issues and risks. His work has supported the development, regulatory approval, and market acceptance of products. Additionally, he has been instrumental in implementing innovative strategies and technologies for global clinical trial programming.